Key Points
- Major shareholder Chidozie Ugwumba sold a total of 142,787 Clene shares across trades from January 6–21, including 7,923 shares on January 16 at an average of $5.13, generating roughly $753,500 in proceeds (SEC-filed).
- After these disposals Ugwumba directly owns 642,375 shares valued at about $3.30 million, a reported 1.22% reduction in their position.
- Clene is a clinical-stage biopharma with a market cap of $56.3M; it recently missed quarterly EPS/revenue expectations and carries a consensus analyst rating of "Moderate Buy" with a $32.60 average price target.
Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 7,923 shares of the company's stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $5.13, for a total transaction of $40,644.99. Following the sale, the insider directly owned 642,375 shares in the company, valued at $3,295,383.75. This trade represents a 1.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The shares were sold at an average price of $5.05, for a total transaction of $61,200.95.
- On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The stock was sold at an average price of $4.80, for a total transaction of $59,673.60.
- On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The stock was sold at an average price of $5.10, for a total value of $64,071.30.
- On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The shares were sold at an average price of $5.12, for a total value of $100,459.52.
- On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The stock was sold at an average price of $4.89, for a total value of $127,653.45.
- On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The shares were sold at an average price of $5.50, for a total value of $179,877.50.
- On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The shares were sold at an average price of $6.27, for a total value of $56,900.25.
- On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The stock was sold at an average price of $6.09, for a total value of $19,457.55.
- On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The stock was sold at an average price of $6.29, for a total transaction of $24,770.02.
- On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The shares were sold at an average price of $6.04, for a total transaction of $18,790.44.
Clene Price Performance
Shares of Clene stock opened at $5.19 on Thursday. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50. The firm has a market cap of $56.31 million, a PE ratio of -1.53 and a beta of 0.87. The company has a 50 day simple moving average of $6.85 and a two-hundred day simple moving average of $6.49.
Clene (NASDAQ:CLNN - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.25). The firm had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.06 million. As a group, research analysts anticipate that Clene Inc. will post -5.19 earnings per share for the current year.
Wall Street Analysts Forecast Growth
CLNN has been the subject of several research analyst reports. Benchmark reaffirmed a "buy" rating on shares of Clene in a research note on Thursday, December 4th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Clene in a research note on Friday, January 9th. D. Boral Capital reiterated a "buy" rating and set a $23.00 price target on shares of Clene in a research report on Friday, January 9th. Finally, UBS Group restated a "buy" rating on shares of Clene in a report on Wednesday, December 3rd. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $32.60.
Check Out Our Latest Report on Clene
Hedge Funds Weigh In On Clene
A number of large investors have recently bought and sold shares of CLNN. Lunt Capital Management Inc. boosted its holdings in shares of Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company's stock worth $315,000 after purchasing an additional 1,250 shares during the period. Jones Financial Companies Lllp bought a new position in Clene during the 3rd quarter valued at approximately $29,000. Jane Street Group LLC bought a new position in Clene during the 2nd quarter valued at approximately $47,000. Finally, Scoggin Management LP lifted its holdings in Clene by 42.8% in the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company's stock worth $558,000 after buying an additional 42,750 shares during the period. 23.28% of the stock is owned by hedge funds and other institutional investors.
About Clene
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
